-
FDA rejects Aveo kidney cancer drug, asks for additional trial
Jun 10, 13 FDA warningsAveo Oncology said the Food and Drug Administration denied approval for its experimental kidney cancer drug citing inconsistent trial results and asked for an additional study.
In a complete response letter to the company, the health regulator said inconsistent survival data from the drug tivozanib’s trials made the results “uninterpretable and inconclusive.
(Reporting by Esha Dey in Bangalore)
###
(Reuters)Also in this section:
Subscribe to the "News" RSS Feed 
TOP ۞
